Earlier CMS Review Could Improve Drug Labels, Ex-FDA Official Says

 
• By Sarah Karlin-Smith
  
picture of a generic drug label, zoomed in over the side effects section
More eyes and perspectives on Rx labels premarket might help avoid post-market payer complications. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership